Changes in cerebral autoregulation, stroke-related blood biomarkers, and autonomic regulation after patent foramen ovale closure in severe migraine patients

CNS Neurosci Ther. 2023 Oct;29(10):3031-3042. doi: 10.1111/cns.14244. Epub 2023 May 8.

Abstract

Aims: This study aimed to investigate changes in dynamic cerebral autoregulation (dCA), 20 stroke-related blood biomarkers, and autonomic regulation after patent foramen ovale (PFO) closure in severe migraine patients.

Methods: Patent foramen ovale severe migraine patients, matched non-PFO severe migraine patients, and healthy controls were included. dCA and autonomic regulation were evaluated in each participant at baseline, and within 48-h and 30 days after closure in PFO migraineurs. A panel of stroke-related blood biomarkers was detected pre-surgically in arterial-and venous blood, and post-surgically in the arterial blood in PFO migraineurs.

Results: Forty-five PFO severe migraine patients, 50 non-PFO severe migraine patients, and 50 controls were enrolled. The baseline dCA function of PFO migraineurs was significantly lower than that of non-PFO migraineurs and controls but was rapidly improved with PFO closure, remaining stable at 1-month follow-up. Arterial blood platelet-derived growth factor-BB (PDGF-BB) levels were higher in PFO migraineurs than in controls, which was immediately and significantly reduced after closure. No differences in autonomic regulation were observed among the three groups.

Conclusion: Patent foramen ovale closure can improve dCA and alter elevated arterial PDGF-BB levels in migraine patients with PFO, both of which may be related to the preventive effect of PFO closure on stroke occurrence/recurrence.

Keywords: autonomic regulation; dynamic cerebral autoregulation; migraine; patent foramen ovale; stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Becaplermin
  • Biomarkers
  • Cardiac Catheterization / adverse effects
  • Foramen Ovale, Patent* / surgery
  • Humans
  • Migraine Disorders*
  • Stroke* / etiology
  • Treatment Outcome

Substances

  • Becaplermin
  • Biomarkers